Published on | 2 weeks ago
Programmes MSCAExecutive summary
The COFUND programme was introduced in 2007 as a new MSC Action in FP7. Since then, 17 calls for proposals have been published. COFUND programmes award fellowships to doctoral and postdoctoral researchers to focus on scientific and transferable training and career development and improved employability, both in the academic and non-academic sector.
Applicants submit proposals for new or existing doctoral or postdoctoral programmes with an impact on the enhancement of human resources in Research & Innovation (R&I) at regional, national or international level. Proposed programmes have a bottom-up approach, with flexibility/freedom for the researchers to define their research topic and choose their supervisor.
This report presents the outcomes of a Feedback to Policy exercise focusing on the COFUND action and provides recommendations at both a practical and a policy level. It is part of a broader Feedback to Policy effort in which the actions are reviewed based on feedback from key stakeholders in order to ensure that the MSCA remain fit for purpose.
The report is divided into 4 chapters:
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.